Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

terminated133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

NCT04541225
withdrawnphase_1

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

NCT05191004
withdrawnphase_1

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

NCT05191017

Clinical Trials (3)

Showing 3 of 3 trials
NCT04541225Phase 1

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Terminated
NCT05191004Phase 1

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Withdrawn
NCT05191017Phase 1

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3